Volkswagen Launches €28,000 ID. Cross EV as Europe’s Electric Vehicle Demand Accelerates 
TSMC Q2 Revenue Surges 36% as AI Chip Demand Powers Growth Ahead of Earnings 
Rio Tinto Reports Strong Q2 Iron Ore Sales, Maintains 2026 Production Outlook 
SK Hynix Stock Soars as AI Memory Demand Outlook Fuels Chip Rally 
Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand 
Nippon Paint Reportedly Offers Up to €7.5 Billion for Akzo Nobel Decorative Paints Business 
Australia Flags Child Safety Gaps at Apple, Meta, Google Over Online Sexual Extortion 
Apple Intelligence Cleared for China as Alibaba and Baidu AI Power iPhone Features 
SoftBank Corp Partners With Sierra to Expand AI Customer Support Across Japan 
Richemont Q1 Sales Beat Forecast as Cartier Demand Drives Strong Growth 
Stellantis Q2 Vehicle Shipments Rise 10% as North America Drives Growth 
Arm Stock Falls After HSBC Downgrade, Citing Limited Near-Term AI Upside 
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors 
Mastercard Explores Sale of Majority Stake in UK Payments Firm Vocalink: Report 
Taiwan Mangoes Head to Europe as Premium Fruit Exports Expand 
Stripe, Advent Offer $53 Billion Deal to Acquire PayPal: Reuters 
DeepSeek Eyes China IPO as AI Startup Seeks $71 Billion Valuation in New Funding Round 
YAVNE, Israel, Jan. 19, 2016 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated, biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release financial results for the three and twelve months ended December 31, 2015, at 7:00 a.m. Eastern time on January 25, 2016.
Following the release, MediWound's management will host a conference call for the investment community beginning at 8:30 a.m. ET on Monday, January 25, 2016, to discuss the financial results and to answer questions.
Shareholders and other interested parties may participate in the conference call by dialing (877) 280-2296 (domestic) or (1809) 212-925 (Israel) and entering passcode 8854485. The call also will be broadcast live on the Internet on the Company’s website at www.mediwound.com.
A replay of the call will be accessible two hours after its completion through February 1, 2016 by dialing (866) 932-5017 (domestic) or (800) 358-7735 (UK) and entering passcode 8854485. The call will also be archived on the Company website for 90 days at www.mediwound.com.
About MediWound Ltd.
MediWound is a fully integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutics based on its patented proteolytic enzyme technology to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds. MediWound’s first innovative biopharmaceutical product, NexoBrid, received marketing authorization from the European Medicines Agency for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full-thickness thermal burns and was launched in Europe. NexoBrid represents a new paradigm in burn care management, and clinical trials have demonstrated, with statistical significance, its ability to non-surgically and rapidly remove the eschar earlier and, without harming viable tissues. For more information, please visit www.mediwound.com.
Contacts: Sharon Malka Chief Financial and Operations Officer MediWound [email protected] Anne Marie Fields Senior Vice President LHA 212-838-3777 [email protected]
